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Summary The effect of epidermal growth factor (hEGF) on intestinal epithelial damage by melphalan was
explored in CBA mice. Human EGF was administered in doses of 100 pgkg-1 or 1000mgkg1 using a variety
of schedules. Mucosal damage was assessed 4, 8 and 13 days later, by [14C]-xylose uptake and by
microcolony survival ofjejunum, ileum and colon. The only regimen to show enhanced jejunal crypt survival
was administration of hEGF, 100 jgkg-1, i.p., 8 hourly, beginning 24h before melphalan treatment. Oral
administration of hEGF had no effect on melphalan induced damage nor on subsequent recovery of intestinal
mucosa. Activity of hEGF in mice was confirmed by demonstration of precocious eyelid opening in newborn
mice. No consistent protective or restorative effect of hEGF on melphalan-induced intestinal epithelial
damage could be demonstrated with the doses and schedules used.
Epidermal growth factor (EGF) is a 53 amino acid
peptide, mol. wt 6045, initially isolated from the
submaxillary glands of adult male mice (Cohen,
1962; Cohen & Taylor, 1974; Carpenter & Cohen,
1979). Mouse EGF (mEGF) stimulated precocious
eyelid opening and incisor eruption in newborn
mice due to promotion of epidermal growth and
increased keratinization (Cohen, 1962; Cohen &
Elliott, 1963; Carpenter & Cohen, 1979). A
polypeptide from human urine, urogastrone, which
inhibits gastric acid secretion and promotes gastric
mucosal healing, is probably the human equivalent
(hEGF) of mouse EGF (Gregory, 1975). The two
polypeptides are highly homologous, have identical
biological effects and cross-react in many antibody
systems (Cohen & Carpenter, 1975; Gregory, 1975;
Carpenter & Cohen, 1979). Epidermal growth
factor stimulates growth of a wide variety of
epidermal cells in vivo and in vitro, including
transformed lines, and of many mesodermal cells
including mouse and human fibroblasts and
vascular endothelial cells (Gospodarowicz et al.,
1978; Cohen & Taylor, 1974; Carpenter & Cohen,
1979).
In man, hEGF occurs in submandibular glands
and Brunners glands (Elder et al., 1978) and in
much lower concentrations in the thyroid gland,
jejunum and kidney (Hirata & Orth, 1979).
Epidermal growth factor inhibits gastric acid
secretion in man, dogs and rats (Gregory, 1975;
Bower et al., 1975; Koffman et al., 1982), while
non-anti-secretory doses protect the gastric mucosa
of cats and rats from aspirin-induced ulceration, by
increasing DNA synthesis (Konturek et al., 1981).
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Rat small intestinal villi have EGF receptors
(Forgue-Lafitte et al., 1980), and mEGF stimulates
DNA synthesis and cell proliferation in adult
murine intestine (Scheving et al., 1979, 1980; Al-
Nafussi & Wright, 1982a; Chabot et al., 1983), and
the development of gastrointestinal enzyme
activities in suckling mice (Malo & Menard, 1982).
Treatment with melphalan in mouse and man
is limited by bone marrow depression, which may
be circumvented by autologous marrow
transplantation, and by gastrointestinal mucosal
toxicity (Millar et al., 1978; McElwain et al., 1979).
Because EGF is trophic for the mouse gastro-
intestinal tract and protects the gastric mucosa
from ulceration, EGF might protect the gastro-
intestinal tract from melphalan damage or enhance
its recovery. We have explored this possibility in
mice and present herewith our preliminary results.
Materials and methods
Adult male and female CBA/ca mice, at least 12
weeks old weighing 20-30gm, were maintained at
22°C with food and water ad libitum. Melphalan
and hEGF administration and assays were all
performed at the same times throughout this study
to eliminate effects from circadian variation in
mouse gastrointestinal tract proliferation (Scheving
et al., 1979, 1980; Al-Nafussi &Wright, 1982b).
Human EGF, urogastrone, was highly purified
biosynthetic material supplied by ICI Pharma-
ceuticals Division (Macclesfield, UK) and G.D.
Searle (High Wycombe, UK). This was dissolved in
sterile water to final concentrations of 10 or
100jugmI-1, and kept frozen until used. The
biological activity of hEGF was confirmed,
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following Cohen (1962) and Moore et al. (1981).
S.c. administration of hEGF 4mgkg-1 daily for 10
days to 9 newborn CBA mice resulted in eyelid
opening on days 8-10, compared with days 14-17
for 11 litter mates treated with saline. Melphalan
(Alkeran, Burrough's Wellcome) was dissolved in
2% acid alcohol (5M HCI: absolute ethanol 1:50)
and diluted in saline immediately prior to i.p.
administration. The doses of 15-20mgkg-1 i.p.
were chosen to result in 30-70% survival of
jejunum crypts. Control mice received water or
saline, 10mlkg-1 i.p.
Four days after melphalan treatment, and then
every 3-5 days until sacrifice, [14C]-xylose uptake
was measured. Mice were anaesthetised with ether,
0.5pCi [14C]-xylose (Amersham International)
administered by oropharyngeal tube and tail vein
blood obtained 30 min later. A Packard Oxidiser
306 (United Technologies Packard) was used to
estimate 14C; 14CO2 was trapped in 8-10ml of
Carbosorb (Packard) and added to 13ml of
Permafluor V scintillant (Packard). Samples were
counted in a P-counter and uptake of [14C]-xylose
calculated as a percentage of the administered dose
per ml of blood. No 14C was detectable 3 days
after [14C]-xylose administration.
On days 4, 7 or 8, and 13 after melphalan
treatment groups of mice were killed, the intestine
excised and surviving cryptogenic cells assessed
using a modification of the method of Withers &
Elkind (1970), described by Millar et al. (1978).
Two or three segments ofjejunum and one each of
ileum and colon were taken from each mouse. The
number of regenerating crypts per circumference of
transverse 4-5pm formalin-fixed sections stained
with haematoxylin and eosin, were expressed as a
percentage of the number of crypts per circum-
ference in normal mice.
Results are presented as the mean (±s.e.) for 3-6
mice, or of the ratio for percentages, and compared
using the t-test for small samples.
Results
Melphalan, hEGfandgut damage at 4 and 7 days
Groups of 3 mice were treated with melphalan, 15
or 20mgkg-1, or saline, i.p. Two hours before
melphalan or saline treatment hEGF (100pg kg-1)
or water was administered i.p. and continued 8
hourly for 4 days (total 12 doses). Jejunum
microcolonies and ['4C]-xylose uptake were
determined on days 4 and 7 (Figure 1).
The melphalan-treated mice all lost weight, and
the loss tended to be greater with hEGF. Uptake of
[14C]-xylose showed no significant differences from
controls, nor any effect of hEGF treatment.
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Figure 1 (a) Weight (day 4), (b) [14C]-xylose uptake
and (c) jejunum microcolonies 4 and 7 days after
treatment of mice with melphalan 15mgkg-1 i.p.
(M15) or 20mgkg-1 i.p. (M20) or saline (C), with
(shaded) or without hEGF lOOygkg-' i.p., 8 hourly,
12 doses.
Treatment with hEGF further reduced jejunal crypt
survival after melphalan 15mgkg-1 i.p. from 97%
to 71% (P<0.02) on day 4, and from 90% to 73%
(P<0.05) on day 7. Treatment with hEGF alone
had no effect in either assay. This suggested that
commencing hEGF 2h before melphalan might be
detrimental and other regimens were therefore
explored.
Six different regimens ofhEGFadministration
Groups of 3 mice received melphalan (17.5mgkg 1;
i.p.) on day 0, with hEGF i.p. in one of 6 regimens
shown on Table I. When hEGF was given on day
0, it preceded melphalan by 2h, except in group 6
where hEGF was commenced 6h after melphalan.
On day 4, [14C]-xylose uptake and gut
microcolonies were assessed (Table I).
Only administration of hEGF (100pgkg-1; i.p.;
8 hourly) beginning 24h before melphalan (regimen
5) increased jejunal crypt survival (P<0.01). No
significant effects of hEGF were seen on ileum and
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Table I Regimens of administration of hEGF
Dose Dose Day(s) of Jejunum
melphalan hEGF No. doses hEGF microcolonies
Group mgkg-' igkg-' hEGF/day treatment % control
C 0 Nil Nil Nil 100.0+ 5.7
M 17.5 Nil Nil Nil 38.5+ 3.5
1 17.5 1,000 1 -2 39.9+ 3.4
2 17.5 1,000 1 -1 36.1+ 2.4
3 17.5 1,000 1 1-4 35.5+ 5.5
4 17.5 100 3 -1-.0 46.1+12.4
5 17.5 100 3 -1-4 55.3 + 3.2a
6 17.5 100 3 0-4 45.4+20.4
ap<0.01.
colon microcolonies nor [14C]-xylose uptake after
any ofthe 6 regimens (data not shown).
Delay in administration ofhEGF until 4 days after
melphalan
It was possible that EGF might be effective only
once histological damage was extensive, i.e. from
day 4 onwards. Therefore groups of mice treated
with melphalan (I5mgkg-1, i.p.) on day 0 were
treated with hEGF lOO1gkg-1 i.p. or water i.p. 8
hourly for 8-10 days, beginning either 6h or 4 days
after melphalan. Uptake of [14C]-xylose was
measured on days 4, 8 and 13 and surviving
microcolonies on days 8 and 13 (Figure 2).
Human EGF begun 6h after melphalan
treatment had no effect on survival ofjejunal crypts
or ileum crypts at 8 or 13 days. However, ileum
crypt survival was not reduced by melphalan
(15mgkg-1, i.p.) (Figure 2a). Colon crypt survival
was not affected by melphalan 15mgkg-t i.p. or
by hEGF (data not shown). The low value of [14C]-
xylose uptake in control mice on day 8 is
unexplained, but none of the treated groups
differed significantly from the day 4 control value
or from each other. Delaying hEGF treatment until
4 days after melphalan had no significant effect on
gastrointestinal recovery (Figure 2b). All the treated
mice lost weight, with a nadir at 4-5 days, recovery
by day 8, with no detectable effect of hEGF.
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Figure 2 Jejunum and ileum microcolonies and ["4C]-xylose uptake after treatment of mice with melphalan
15mgkg - i.p. (M 15) with (shaded, A) or without (0) hEGF I100Mgkg
- i.p., 8 hourly, begun either 6h after
melphalan (a) or on day 4 (b), compared with untreated controls (C, *).
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Oral hEGF andmelphalan gut damage
Melphalan (20mgkg-1, i.p.) was given to 2 groups
of 5 mice on day 0. One group received hEGF
(100 pg kg-1) by oropharyngeal tube under light
ether anaesthesia twice daily (9 doses), and the
other group anaesthesia only, beginning
immediately before melphalan administration. On
day 4, there was no difference in gastrointestinal
toxicity between the group treated with topical
hEGF and controls treated only with melphalan
(20mgkg-1, i.p.) (Figure 3).
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Figure 3 (a) Weight, (b) [14C]-xylose uptake, (c)
jejunum and (d) ileum microcolonies (day 4) after
treatment of mice with melphalan 20mgkg-1 i.p.
(M20) with (shaded) or without oral hEGF 100kgkg
twice daily, compared with controls (C).
Discussion
This study failed to show a consistent and
significant protective or restorative effect of hEGF
on mouse gastrointestinal damage from high dose
melphalan. The only significant findings were an
increase in jejunum crypt survival after melphalan
(17.5mgkg-1, i.p.) by hEGF (100pgkg-1, i.p. 8
hourly) begun 24h before melphalan and a decrease
in jejunum crypt survival after melphalan
l5mgkg-1 i.p. by the same dose of hEGF begun
2h before melphalan.
The jejunum is the segment of mouse intestine
most affected by melphalan with damage most
extensive at 4 days when gastrointestinal toxicity is
usually assessed (Millar et al., 1978). However, the
jejunum may be the segment least affected by
exogenous EGF. Synthesis of DNA and cell
proliferation in mouse intestine follows a circadian
rhythm (Scheving et al., 1979, 1980; Al-Naffusi &
Wright, 1982b), which may be related to the
circadian periodicity of EGF in the male mouse
submaxillary gland controlled by the sympathetic
nervous system in response to the dark-light cycle
or to feeding (Krieger et al., 1976). The extent of
stimulation of gastrointestinal proliferation by EGF
depends on the part of the intestine, its phase in the
cycle (Scheving et al., 1979, 1980) and on feeding
(Chabot et al., 1983).
In fasted mice, mEGF (25pg per mouse)
increased DNA synthesis in the jejunum, ileum and
colon (Chabot et al., 1983), but not in the jejunum
of fed mice (Scheving et al., 1979; Chabot et al.,
1983). Cell production, by vincristine metaphase
arrest, was also not increased in the jejunum of fed
mice after mEGF, 10pgkg-1, 8 hourly for 6 doses
(Al-Nafussi & Wright, 1982a). Melphalan-treated
mice tend not to eat and might resemble fasted
mice, who have lower serum levels of endogenous
EGF (Chabot et al., 1983). However, melphalan
damage might promote endogenous EGF release
and stimulation so that exogenous EGF is
ineffective.
The dosage, mode of administration and timing
of hEGF should have been adequate to detect an
effect if hEGF has the same biological effects as
mEGF in mie.= Thus to 0pgkg-1, up to 8 hourly
for up to 10"days, and 10Opgkg-1 (25pg per 25g
mouse) i.p., span the doses and times of
administration of mEGF which affect DNA
synthesis and cell proliferation in murine intestine
(Scheving et al., 1979, 1980; Al-Naffusi & Wright,
1982a,b; Chabot' et al., 1983). Precocious eyelid
opening in newborn mice requires daily doses of 1-
4mgkg-1 mEGF, although 0.3mgkg-1 has a
detectable effect (Cohen, 1962; Moore et al., 1981);
hEGF has a similar potency (Gregory, 1975). The
close homology between mEGF and hEGF makes
it unlikely that failure.to show a protective effect in
murine intestine is due to the use of hEGF. Indeed,
mEGF, 100pgkg-1 i.p. twice daily for 4 days
failed to protect murine jejunum from melphalan
(unpublished observations).
The conclusion from this study is that hEGF, in
the doses and regimens employed, did not protect
the mouse gastrointestinal tract and particularly the
jejunum, from melphalan damage, nor did it
enhance epithelial recovery. No optimal timing of
hEGF administration with respect to melphalan
emerged. However, different scheduling of hEGF
with respect to melphalan and different frequency
I
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and mode of administration of hEGF might be
successful. It remains an attractive possibility to
protect normal tissue with a growth factor to
enable administration of melphalan with less
toxicity or in higher doses. There must be caution,
however, in view of the stimulatory effects of EGF
on transformed as well as normal cells.
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